asp-3026
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01284192)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- ALK tyrosine kinase receptorINHIBITOR
ALK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1- Mol. weight
- 580.76 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545360 ↗
Also known as
- asp3026
- asp3026
- asp-3026
- asp-3026
- asp-3026
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01401504 | Phase 1 | May 1, 2011 | Astellas |
| NCT01284192 | Phase 1 | Dec 1, 2010 | Astellas |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 2 | 2 | 1 | 2010 |
1 organizations
Page 1 / 1